The triterpene hederagenin glucoside saponins and chromane hydrazone 2-(2,3-dihydro-4h-1- benzopyran-4-ylidene) hydrazide as active ingredients of topical formulation to treat cutaneous leishmaniasis

Abstract

ABSTRACT: Cutaneous leishmaniasis (CL) is an endemic infection worldwide. Due to variable response to therapy and frequency of relapses, a more effective, safe, and inexpensive treatment is needed. Previously it was reported that the hederagenin glucoside saponins (SS) and chromane hydrazone (TC2) combined in a 1:1 ratio has high potential in antileishmanial therapy since both compounds may alter the survival of Leishmania and the ability to infect adjacent macrophage. In this work, we developed an ointment formulation containing 2% TC2 and 2% SS (w/w) and determined the skin permeation and the absorption but also the acute dermal toxicity by in vitro and in vivo assays.